Raymond James Trust N.A. Grows Holdings in Gilead Sciences, Inc. (GILD)

Raymond James Trust N.A. grew its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 7.7% during the third quarter, HoldingsChannel reports. The firm owned 24,469 shares of the biopharmaceutical company’s stock after acquiring an additional 1,746 shares during the quarter. Raymond James Trust N.A.’s holdings in Gilead Sciences were worth $1,889,000 at the end of the most recent quarter.

A number of other large investors have also recently added to or reduced their stakes in GILD. Bank of New York Mellon Corp lifted its stake in Gilead Sciences by 11.6% during the second quarter. Bank of New York Mellon Corp now owns 30,936,970 shares of the biopharmaceutical company’s stock worth $2,191,575,000 after purchasing an additional 3,221,439 shares in the last quarter. Swedbank lifted its stake in Gilead Sciences by 103.7% during the third quarter. Swedbank now owns 3,906,172 shares of the biopharmaceutical company’s stock worth $301,596,000 after purchasing an additional 1,988,987 shares in the last quarter. Natixis lifted its stake in Gilead Sciences by 4,550.6% during the second quarter. Natixis now owns 1,913,535 shares of the biopharmaceutical company’s stock worth $135,555,000 after purchasing an additional 1,872,389 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. lifted its stake in Gilead Sciences by 1,631.7% during the second quarter. Los Angeles Capital Management & Equity Research Inc. now owns 997,656 shares of the biopharmaceutical company’s stock worth $70,674,000 after purchasing an additional 940,044 shares in the last quarter. Finally, Sanders Capital LLC lifted its stake in Gilead Sciences by 7.0% during the second quarter. Sanders Capital LLC now owns 10,579,575 shares of the biopharmaceutical company’s stock worth $804,126,000 after purchasing an additional 696,200 shares in the last quarter. Institutional investors own 77.99% of the company’s stock.

GILD has been the topic of a number of recent research reports. BidaskClub raised Gilead Sciences from a “hold” rating to a “buy” rating in a research report on Thursday, October 11th. Mizuho reaffirmed a “buy” rating and set a $94.00 price objective on shares of Gilead Sciences in a research report on Friday, August 10th. Piper Jaffray Companies set a $85.00 price objective on Gilead Sciences and gave the stock a “buy” rating in a research report on Wednesday, September 12th. Zacks Investment Research raised Gilead Sciences from a “hold” rating to a “buy” rating and set a $86.00 price objective on the stock in a research report on Wednesday, July 18th. Finally, ValuEngine raised Gilead Sciences from a “sell” rating to a “hold” rating in a research report on Friday, September 28th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and two have given a strong buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $88.24.

NASDAQ:GILD opened at $76.31 on Wednesday. The firm has a market capitalization of $100.09 billion, a P/E ratio of 8.91, a price-to-earnings-growth ratio of -3.92 and a beta of 1.01. The company has a debt-to-equity ratio of 1.23, a quick ratio of 2.92 and a current ratio of 3.00. Gilead Sciences, Inc. has a 12 month low of $64.27 and a 12 month high of $89.54.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Wednesday, July 25th. The biopharmaceutical company reported $1.91 EPS for the quarter, beating the consensus estimate of $1.56 by $0.35. The firm had revenue of $5.65 billion for the quarter, compared to analyst estimates of $5.20 billion. Gilead Sciences had a return on equity of 41.57% and a net margin of 9.52%. Gilead Sciences’s revenue for the quarter was down 20.9% compared to the same quarter last year. During the same quarter in the prior year, the company posted $2.56 earnings per share. Analysts predict that Gilead Sciences, Inc. will post 6.56 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which was paid on Thursday, September 27th. Investors of record on Friday, September 14th were issued a $0.57 dividend. This represents a $2.28 annualized dividend and a yield of 2.99%. The ex-dividend date of this dividend was Thursday, September 13th. Gilead Sciences’s dividend payout ratio (DPR) is presently 26.64%.

In related news, Director John C. Martin sold 50,000 shares of the stock in a transaction on Monday, October 1st. The stock was sold at an average price of $78.04, for a total value of $3,902,000.00. Following the transaction, the director now owns 3,067,762 shares of the company’s stock, valued at $239,408,146.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders sold 150,000 shares of company stock worth $11,502,500 in the last three months. 1.16% of the stock is currently owned by corporate insiders.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics in the areas of unmet medical needs in the United States, Europe, and internationally. The company's products include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Atripla, Truvada, Viread, Emtriva, and Tybost for the treatment of human immunodeficiency virus (HIV) infection in adults; and Vosevi, Vemlidy, Epclusa, Harvoni, Sovaldi, Viread, and Hepsera products for treating liver diseases.

See Also: Penny Stocks, Risk and Reward Factors

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply